Evaluating CALR Allele Burden for Diagnosis and Monitoring of CALR Mutated Myeloproliferative Syndromes
Led by University Hospital, Angers · Updated on 2026-03-06
260
Participants Needed
10
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the importance of monitoring CALR allele burden as a molecular marker to understand disease progression in patients with CALR-mutated myeloproliferative neoplasms MPNs. It builds on earlier findings from a local study of 45 patients, which showed that quantifying CALR mutations could predict outcomes independently of established risk scores. The study plans to include a large group of 260 patients with various types of CALR-mutated MPNs to better model how CALR allele burden changes over time.
Participants will have their blood collected at diagnosis and during follow-up visits, with up to one sample per year for a maximum of three years. This allows researchers to measure the CALR allele burden through DNA extraction and fragment analysis. Additionally, at diagnosis, a mutational profile will be studied using advanced sequencing methods. The study will also assess a clinical and biological scoring system to determine disease progression in Essential Thrombocythemia and Myelofibrosis cases.
During the study, participants will provide blood samples at diagnosis and annually for up to three years. Researchers will evaluate the relationship between CALR allele burden changes and disease progression using this data. They will also analyze characteristics like pathology type, treatment, and additional mutations to understand their impact on allele burden trajectories. The main outcome is to determine how these trajectories relate to the time until disease progression, supporting better monitoring and management of CALR-mutated MPNs.
CONDITIONS
Brief Title
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Research Team
L
Laurane COTTIN, Doctor
E
Emma BLANCHET
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with CALR mutated myeloproliferative neoplasm between 2006 and 2020
Have at least one blood sample available at diagnosis or before cytoreductive treatment
Signed consent to participate in the study
Included or consenting to be included in the national clinical-biological database of France Intergroupe Syndrome Myéloprolifératifs (FIM)
You will not qualify if you...
Having another active hematological disease or cancer at the time of diagnosis
Being under a legal protection scheme or unable to give consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for consent and eligibility confirmation
Diagnostic Evaluation
Duration - At diagnosis
Blood samples are collected at diagnosis for CALR mutation quantification and mutational landscape analysis.
1 visit (in-person) at diagnosis
Long-term Monitoring
Duration - Up to 3 years
Participants provide up to 1 blood sample per year for up to 3 years to monitor CALR allele burden and disease progression using a clinicobiological score.
Up to 3 visits (in-person), approximately 1 visit per year
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Similar Trials
Phase 1 Study of CIML NK Cell Infusion with IL-2 for Treating Relapsed Myeloid Diseases After Stem Cell Transplantation in Adults and Children 12 Years and Older
Phase 3 Randomized Study of INCA033989 Versus Best Available Therapy for Essential Thrombocythemia with CALR Mutation After Prior Cytoreductive Treatment
Randomized Study Comparing ASTX727 Alone or with Iadademstat for Advanced Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
Phase 1 Study of Oral GLB-001 to Evaluate Safety and Effectiveness in Adults with Relapsed or Refractory Myeloid Malignancies
Study of CMV-MVA Triplex Vaccine and Letermovir to Boost CMV Immunity and Prevent Infection in Haploidentical Stem Cell Transplant Donors and Recipients
Phase II Study of Reduced Intensity Conditioning and Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in Blood Cancers
Finding the Best Dose of N-Acetylcysteine for Adults with Myeloproliferative Neoplasms including Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis
Asian Registry Study of Patients with Myeloproliferative Neoplasms
Including Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis
Conducted Across Multiple Asian Countries
Study of Apixaban or Rivaroxaban Compared to Low-Dose Aspirin for Preventing Blood Clots in Adults with JAK2V617F-positive Myeloproliferative Neoplasms
Phase 2 Study Comparing Bendamustine Versus Ruxolitinib with Fludarabine and Busulfan Conditioning in Adults Undergoing Haploidentical Stem Cell Transplant for Blood Cancers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Sequential mutational evaluation of CALR -mutated myeloproliferative neoplasms with thrombocytosis reveals an association between CALR allele burden evolution and disease progression.